{"pmid":32353191,"title":"Response to \"Dose rationale for favipiravir use in patients infected with SARS-CoV-2\".","text":["Response to \"Dose rationale for favipiravir use in patients infected with SARS-CoV-2\".","We appreciate the letter by Eloy P., et al for their comments and complement regarding our review(1-2) . Two independent in vitro studies indicated that favipiravir (T-705) inhibited SARS-CoV-2 replication in Vero E6 cells with EC50 values of 61.88 muM (9.4 mug/mL)(3) and >100 muM (15.7 mug/mL)(4) , respectively. Data from the authors' group suggests an EC50 value in the range 40-80 microg/mL (X. de Lamballerie & F. Touret, unpublished results). I agree with the authors' assumption that favipiravir shows similar EC50 against SARS-CoV-2 and EBOV. As favipiravir is a prodrug that requires metabolic activation through ribosylation and phosphorylation in the host cells to form its triphosphate form (favipiravir-RTP), we think that variation in favipiravir activation by the cultured cells may, at least partially, contribute to the difference in the in vitro EC50 among studies.","Clin Pharmacol Ther","Du, Yin-Xiao","Chen, Xiao-Ping","32353191"],"abstract":["We appreciate the letter by Eloy P., et al for their comments and complement regarding our review(1-2) . Two independent in vitro studies indicated that favipiravir (T-705) inhibited SARS-CoV-2 replication in Vero E6 cells with EC50 values of 61.88 muM (9.4 mug/mL)(3) and >100 muM (15.7 mug/mL)(4) , respectively. Data from the authors' group suggests an EC50 value in the range 40-80 microg/mL (X. de Lamballerie & F. Touret, unpublished results). I agree with the authors' assumption that favipiravir shows similar EC50 against SARS-CoV-2 and EBOV. As favipiravir is a prodrug that requires metabolic activation through ribosylation and phosphorylation in the host cells to form its triphosphate form (favipiravir-RTP), we think that variation in favipiravir activation by the cultured cells may, at least partially, contribute to the difference in the in vitro EC50 among studies."],"journal":"Clin Pharmacol Ther","authors":["Du, Yin-Xiao","Chen, Xiao-Ping"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32353191","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1878","keywords":["covid-19","favipiravir","pharmacokinetics"],"e_drugs":["triphosphoric acid","favipiravir"],"weight":0,"_version_":1666138495750504448,"score":9.490897,"similar":[{"pmid":32350860,"title":"Dose rationale for favipiravir use in patients infected with SARS-CoV-2.","text":["Dose rationale for favipiravir use in patients infected with SARS-CoV-2.","We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID-19(1) . We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS-CoV-2 are 10-60 microg/ml and 9.4 microg/ml(4) , respectively. However results obtained by our working group suggest a higher value of EC50 , in the range 40-80 microg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS-CoV-2 is in the same range as against EBOV.","Clin Pharmacol Ther","Eloy, Philippine","Solas, Caroline","Touret, Franck","Mentre, France","Malvy, Denis","de Lamballerie, Xavier","Guedj, Jeremie","32350860"],"abstract":["We read with a great interest the paper by Du et Chen suggesting dosing regimen of favipiravir in COVID-19(1) . We would like to complement their observations with our PK/PD experience of favipiravir against Ebola virus (EBOV). The drug EC50 against EBOV and SARS-CoV-2 are 10-60 microg/ml and 9.4 microg/ml(4) , respectively. However results obtained by our working group suggest a higher value of EC50 , in the range 40-80 microg/ml (X. de Lamballerie & F. Touret, unpublished results). We therefore use the conservative assumption that the drug EC50 against SARS-CoV-2 is in the same range as against EBOV."],"journal":"Clin Pharmacol Ther","authors":["Eloy, Philippine","Solas, Caroline","Touret, Franck","Mentre, France","Malvy, Denis","de Lamballerie, Xavier","Guedj, Jeremie"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350860","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/cpt.1877","keywords":["covid","antiviral drugs","favipiravir","pharmacokinetics"],"e_drugs":["favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138495693881344,"score":838.1811},{"pmid":32251767,"pmcid":"PMC7127386","title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","text":["Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.","An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits.","Antiviral Res","Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling","32251767"],"abstract":["An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed. We evaluated the in vitro antiviral effect of compounds that were previously reported to inhibit coronavirus replication and compounds that are currently under evaluation in clinical trials for SARS-CoV-2 patients. We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estimated 50% effective concentration at 23.15 muM, 26.63 muM, 2.55 muM and 0.46 muM, respectively. Ribavirin or favipiravir that are currently evaluated under clinical trials showed no inhibition at 100 muM. Synergy between remdesivir and emetine was observed, and remdesivir at 6.25 muM in combination with emetine at 0.195 muM may achieve 64.9% inhibition in viral yield. Combinational therapy may help to reduce the effective concentration of compounds below the therapeutic plasma concentrations and provide better clinical benefits."],"journal":"Antiviral Res","authors":["Choy, Ka-Tim","Wong, Alvina Yin-Lam","Kaewpreedee, Prathanporn","Sia, Sin Fun","Chen, Dongdong","Hui, Kenrie Pui Yan","Chu, Daniel Ka Wing","Chan, Michael Chi Wai","Cheung, Peter Pak-Hang","Huang, Xuhui","Peiris, Malik","Yen, Hui-Ling"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251767","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104786","keywords":["abstract","covid-19","emetine","homoharringtonine","lopinavir","remdesivir","ritonavir"],"e_drugs":["remdesivir","Ribavirin","Lopinavir","Emetine","favipiravir","Homoharringtonine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490993115138,"score":319.72525},{"pmid":32475019,"title":"Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.","text":["Pharmacokinetics of Favipiravir in Critically Ill Patients with COVID-19.","Since December 2019, a novel coronavirus (SARS-CoV-2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 h) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and EC50 (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19.","Clin Transl Sci","Irie, Kei","Nakagawa, Atsushi","Fujita, Hirotoshi","Tamura, Ryo","Eto, Masaaki","Ikesue, Hiroaki","Muroi, Nobuyuki","Tomii, Keisuke","Hashida, Tohru","32475019"],"abstract":["Since December 2019, a novel coronavirus (SARS-CoV-2) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID-19). The anti-retroviral drug favipiravir (FPV) has been experimentally used for COVID-19 treatment since March 2020 in Japan. However, the pharmacokinetics of FPV in critically ill patients is unknown. We measured the serum concentration of FPV using high-performance liquid chromatography in patients with severe COVID-19 who were admitted to the intensive care unit and placed on mechanical ventilation. The patients were administered 1600 mg of FPV twice daily on Day 1, followed by 600 mg twice daily from Day 2 to Day 5 (or more if needed). Suspensions of FPV tablets were administered through a nasogastric tube. Seven patients were enrolled in this study. Forty-nine blood samples were obtained from the eligible patients to evaluate FPV concentration. The FPV trough (after 8-12 h) concentrations of most samples were lower than the lower limit of quantification (1 microg/mL) and EC50 (9.7 microg/mL) against SARS-CoV-2 previously tested in vitro. FPV trough concentration in critically ill patients was much lower than that of healthy subjects in a previous clinical trial, which is a cause for great concern. Further study is required to determine the optimal strategy for treatment of patients with severe COVID-19."],"journal":"Clin Transl Sci","authors":["Irie, Kei","Nakagawa, Atsushi","Fujita, Hirotoshi","Tamura, Ryo","Eto, Masaaki","Ikesue, Hiroaki","Muroi, Nobuyuki","Tomii, Keisuke","Hashida, Tohru"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32475019","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/cts.12827","keywords":["covid-19","favipiravir","sars-cov-2"],"locations":["Japan","optimal"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"topics":["Treatment"],"weight":1,"_version_":1668341932632309761,"score":314.69937},{"pmid":32150618,"pmcid":"PMC7108130","title":"In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","text":["In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).","BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.","Clin Infect Dis","Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang","32150618"],"abstract":["BACKGROUND: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. METHODS: The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells. Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile. RESULTS: Hydroxychloroquine (EC50=0.72 muM) was found to be more potent than chloroquine (EC50=5.47 muM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. CONCLUSIONS: Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro."],"journal":"Clin Infect Dis","authors":["Yao, Xueting","Ye, Fei","Zhang, Miao","Cui, Cheng","Huang, Baoying","Niu, Peihua","Liu, Xu","Zhao, Li","Dong, Erdan","Song, Chunli","Zhan, Siyan","Lu, Roujian","Li, Haiyan","Tan, Wenjie","Liu, Dongyang"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32150618","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1093/cid/ciaa237","keywords":["chloroquine","hydroxychloroquine","sars-cov-2"],"link_comment_in":"32241791","locations":["Wuhan","China","PBPK","PBPK"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","Chloroquine","chloroquine diphosphate"],"topics":["Treatment"],"weight":1,"_version_":1666138492713828352,"score":270.86545},{"pmid":32429580,"title":"Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).","text":["Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).","Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and interferes with the action of RNA-dependent RNA polymerase of SARS-COV-2. Herein, we report the antiviral activity of remdesivir against human coronavirus 229E (HCoV-229E) compared to known anti-HIV agents. These agents included tenofovir (TFV), 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), alovudine (FLT), lamivudine (3TC), and emtricitabine (FTC), known as nucleoside reverse-transcriptase inhibitors (NRTIs), and a number of 5'-O-fatty acylated anti-HIV nucleoside conjugates. The anti-HIV nucleosides interfere with HIV RNA-dependent DNA polymerase and/or act as chain terminators. Normal human fibroblast lung cells (MRC-5) were used to determine the cytotoxicity of the compounds. The study revealed that remdesivir exhibited an EC50 value of 0.07 microM against HCoV-229E with TC50 of > 2.00 microM against MRC-5 cells. Parent NRTIs were found to be inactive against (HCoV-229E) at tested concentrations. Among all the NRTIs and 5'-O-fatty acyl conjugates of NRTIs, 5'-O-tetradecanoyl ester conjugate of FTC showed modest activity with EC50 and TC50 values of 72.8 microM and 87.5 microM, respectively. These data can be used for the design of potential compounds against other coronaviruses.","Molecules","Parang, Keykavous","El-Sayed, Naglaa Salem","Kazeminy, Assad J","Tiwari, Rakesh K","32429580"],"abstract":["Remdesivir is a nucleotide prodrug that is currently undergoing extensive clinical trials for the treatment of COVID-19. The prodrug is metabolized to its active triphosphate form and interferes with the action of RNA-dependent RNA polymerase of SARS-COV-2. Herein, we report the antiviral activity of remdesivir against human coronavirus 229E (HCoV-229E) compared to known anti-HIV agents. These agents included tenofovir (TFV), 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), alovudine (FLT), lamivudine (3TC), and emtricitabine (FTC), known as nucleoside reverse-transcriptase inhibitors (NRTIs), and a number of 5'-O-fatty acylated anti-HIV nucleoside conjugates. The anti-HIV nucleosides interfere with HIV RNA-dependent DNA polymerase and/or act as chain terminators. Normal human fibroblast lung cells (MRC-5) were used to determine the cytotoxicity of the compounds. The study revealed that remdesivir exhibited an EC50 value of 0.07 microM against HCoV-229E with TC50 of > 2.00 microM against MRC-5 cells. Parent NRTIs were found to be inactive against (HCoV-229E) at tested concentrations. Among all the NRTIs and 5'-O-fatty acyl conjugates of NRTIs, 5'-O-tetradecanoyl ester conjugate of FTC showed modest activity with EC50 and TC50 values of 72.8 microM and 87.5 microM, respectively. These data can be used for the design of potential compounds against other coronaviruses."],"journal":"Molecules","authors":["Parang, Keykavous","El-Sayed, Naglaa Salem","Kazeminy, Assad J","Tiwari, Rakesh K"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429580","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/molecules25102343","keywords":["hcov-229e","nrtis","rna polymerase","sars-cov-2","antiviral","remdesivir"],"e_drugs":["Tenofovir","remdesivir","triphosphoric acid","4'-ethynyl-2-fluoro-2'-deoxyadenosine","Emtricitabine","alovudine","Lamivudine","Nucleosides"],"topics":["Treatment"],"weight":1,"_version_":1667342288415621120,"score":268.0544}]}